Agoracom: Small Cap Investment - Stem Cell Therapeutics - NR: Stem Cell Therapeutics Receives FDA End of Phase II Meeting Date

Welcome To The Stem Cell Therapeutics HUB On AGORACOM

Stem Cell is a public biotechnology company focused on the development and commercialization of drug-based therapies to treat central nervous system diseases.

Dear Agoracom Family,

I want to thank all of you for your patience with us over the past 48 hours and apologize for what was admittedly a botched launch of our new site.

As you can see, we have reverted back to the previous version of the site while we address multiple forum functionality flaws that inexplicably made their way into the launch.

To this end:

1.We have identified 8 fundamental but easily fixable flaws that will be corrected in the coming week, so that you can continue to use the forums exactly as you've been accustomed to.

2.Additionally we will also be implementing a couple of design improvements to "tighten up" the look and feel of the forums.

Sincerely,

George et al

Reply New Message

Back To Forum List View

Moneytospend

Rank: Vice President [?]

Points: 11424 [?]

Votes: 188 Score: 3.2 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

NR: Stem Cell Therapeutics Receives FDA End of Phase II Meeting Date

posted on Oct 08, 2010 03:41PM

Stem Cell Therapeutics Receives FDA End of Phase II Meeting Date

CALGARY, ALBERTA, Oct 08, 2010 (MARKETWIRE via COMTEX News Network) --

Stem Cell Therapeutics Corp. (TSX VENTURE: SSS) ("SCT" or the "Company") wishes to announce that a requested end of Phase II meeting has been reviewed by FDA and a meeting date has been set for December 20, 2010.

Dr. Allen Davidoff, Vice President, Product Development of SCT stated "The Company looks forward to advancing discussions with the FDA regarding the NTx(R)-265 programs. We anticipate that the meeting will focus on a review of the positive safety data generated to-date in administering NTx(R)-265, overall analysis of the clinical efficacy data and the encouraging subgroup analysis of the REGENESIS-LED trial. Importantly we will be exploring the design requirements of pivotal trials for NTx(R)-265 in acute ischemic stroke."

As stated previously, the Company continues to advance as a biotech company considering a range of options, with management focusing its efforts on pursuing the end-of-Phase II meeting with the FDA for the NTx(R)-265 stroke therapy, developing a similar regimen for traumatic brain injury (TBI) while reviewing alternatives for pursuing multiple sclerosis ("MS") as well as various other opportunities.

About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a public biotechnology company (TSX VENTURE: SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The Company's programs aim to repair brain and nerve function lost due to disease or injury. The Company's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury, multiple sclerosis, Huntington's disease, Alzheimer's disease, and ALS.

For further information on Stem Cell Therapeutics Corp., visit www.stemcellthera.com.

Reply New Message

Back To Forum List View

Please to post a reply